Sol-Gel Technologies
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Sol-Gel Technologies sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Sol-Gel Technologies: 15 sponsored US clinical trials, none currently recruiting.
Sol-Gel Technologies sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 9 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gorlin Syndrome, with 1 trials.
Top-decile sponsor footprint
Sol-Gel Technologies ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
NCT06050122
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
NCT05675501
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
NCT04308395
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
NCT04155190
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
NCT04059523
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
NCT03703310
Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream
NCT03727074
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
NCT03761784
A Study of S6G5T3 in the Treatment of Acne Vulgaris
NCT03761810
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
NCT03564145
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
NCT03564119
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
NCT03448939
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
NCT02842021
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
NCT02661958
A Study of DER 45-EV Gel to Treat Rosacea
NCT00940992
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 9 |
Therapeutic Areas
How the Sol-Gel Technologies archive is shaped
15 indexed studies, none listed as recruiting (0% open); 10 completed (67%).
Phase mix: 9 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Gorlin Syndrome (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Sol-Gel Technologies: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Sol-Gel Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Sol-Gel Technologies page
15 registered trials is a research-attention snapshot, not an endorsement of Sol-Gel Technologies or any single study.
- None of Sol-Gel Technologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gorlin Syndrome is the condition Sol-Gel Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gorlin Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sol-Gel Technologies pipeline card: 15 registered trials from official public datasets.Report a data error.